BioSpace News Archive

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter 2022 and provided a corporate update.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results and provided a corporate update for the third quarter of 2022.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate at the following investor healthcare conferences.

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2022 after market close on Monday, November 14, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

DBV Technologies announced that new clinical data on the use of Viaskin™ Peanut 250 μg in peanut-allergic toddlers ages 1 to 3 years will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, which is being held November 10-14, 2022, in Louisville, KY.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended September 30, 2022, and provides a corporate update.

Oblique Therapeutics AB, a biotechnology company focused on new antibody medicines for severe diseases with large unmet medical needs, is pleased to announce the confirmation of Christer Nordstedt MD.PhD. as Chief Executive Officer.

Exyte GmbH, a global leader in the design, engineering, and delivery of high-tech facilities, continues its strong performance during the first nine months of fiscal year 2022 successfully progressing on its accelerated growth path, its ‘Pathway to Ten’.

NanoString Technologies, Inc. and Abcam announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomic solutions.

Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced its financial results for the third quarter ended September 30, 2022 and provided a business update.